India could receive the dengue vaccine as early as next year. According to a report by the

印度可能最快在明年接种登革热疫苗。据一份报告显示，

Times of India

印度时报

, Japanese pharmaceutical giant

，日本制药巨头

Takeda

武田

is planning to launch its dengue vaccine, Qdenga, in India next year. Takeda is collaborating with Hyderabad-based

计划明年在印度推出其登革热疫苗Qdenga。武田正与位于海得拉巴的

Biological E

生物E

(Bio E) to bring the vaccine to the market.

（Bio E）将疫苗推向市场。

#Pahalgam Terrorist Attack

#帕哈甘恐怖袭击

India stares at a 'water bomb' threat as it freezes Indus Treaty

印度正面临“水炸弹”威胁，因冻结印度河水条约

India readies short, mid & long-term Indus River plans

印度准备短期、中期和长期的印度河计划

Shehbaz Sharif calls India's stand 'worn-out narrative'

谢里夫称印度的立场是“陈词滥调”

Derek Wallace, president of Takeda's Global Vaccine Business Unit, told

德里克·华莱士，武田全球疫苗业务部总裁，告诉

TOI

印度时报

that the $23 billion company will adopt a “tiered pricing model for its first global vaccine to maximize access.”

这家价值230亿美元的公司将为其首个全球疫苗采用“分层定价模式，以最大限度地扩大获取渠道”。

Currently, clinical trials for the vaccine are underway, with Takeda expecting to secure a license for Qdenga in India by 2026. The company has already submitted a comprehensive data package to support the vaccine's registration in 40 countries.

目前，该疫苗的临床试验正在进行中，武田制药预计将在 2026 年之前获得 Qdenga 在印度的上市许可。该公司已经提交了一套全面的数据资料包，以支持该疫苗在 40 个国家的注册。

Takeda plans to introduce the vaccine in both private and public sectors simultaneously. While the vaccine will initially target the pediatric population in line with India’s National Immunization Program, it will also be available to adults in the private sector, Wallace explained.

武田计划同时在私营和公共部门推出该疫苗。华莱士解释说，虽然该疫苗最初将依照印度的国家免疫规划针对儿科人群，但也将在私营部门提供给成年人。

Qdenga is a tetravalent live-attenuated vaccine targeting all four dengue serotypes. It requires a two-dose regimen with a three-month interval. Since its global launch in 2023, over 10 million doses have been sold worldwide.

Qdenga 是一种四价减毒活疫苗，针对所有四种登革病毒血清型。它需要两剂接种方案，间隔三个月。自2023年全球推出以来，已在全球销售超过1000万剂。

Live Events

现场活动

Takeda's collaboration with Bio E is essential for local vaccine production in India, as dengue impacts half of the world’s population. 'Our goal is to produce 100 million doses annually by the end of the decade, with Bio E contributing half of that,' Wallace said. Bio E will also serve as Takeda's exclusive manufacturer for multi-dose vials, which are preferred in public health programs due to their cost-effectiveness, optimized storage, and simplified distribution..

武田与Bio E的合作对于印度当地的疫苗生产至关重要，因为登革热影响着全球一半的人口。华莱士表示：“我们的目标是到本十年末每年生产1亿剂，其中Bio E将贡献一半。” Bio E还将成为武田多剂量瓶的独家制造商，由于其具有成本效益、存储优化和简化的分发流程，这种多剂量瓶在公共卫生项目中更受青睐。

While Takeda's German facility currently manufactures single-dose vials, Bio E will produce both single and multi-dose formats in India. Takeda’s long-term goal is to establish a complete vaccine production value chain in India, with plans to manufacture 100% of the doses locally in phases.

虽然武田的德国工厂目前生产单剂量瓶装，但印度的生物E公司将生产单剂量和多剂量两种格式。武田的长期目标是在印度建立一个完整的疫苗生产价值链，并计划分阶段在当地生产全部剂量。

Over the past two decades, dengue cases have increased eightfold due to factors like climate change, urbanization, and globalization. Last year, India reported nearly 300,000 dengue cases. Before launching the vaccine in India, Takeda is focused on building trust with government stakeholders and establishing public-private partnerships to ensure broad vaccine access.

过去二十年中，由于气候变化、城市化和全球化等因素，登革热病例增加了八倍。去年，印度报告了近 30 万例登革热病例。在印度推出该疫苗之前，武田制药正专注于与政府利益相关者建立信任，并建立公私合作伙伴关系，以确保广泛的疫苗接种。

Wallace emphasized the importance of understanding public health program roadmaps and generating the necessary data to support these initiatives..

华莱士强调了理解公共卫生项目路线图的重要性，并生成支持这些举措所需的数据。

Takeda’s research into a dengue vaccine dates back to the 1980s, with initial studies in Thailand and later collaboration with the U.S. Centers for Disease Control and Prevention (CDC). In 2012, the company conducted the TIDES study, one of its largest global trials, involving 20,000 children across eight dengue-endemic countries..

武田对登革热疫苗的研究可以追溯到上世纪80年代，最初在泰国开展研究，后来与美国疾病控制与预防中心 (CDC) 展开合作。2012年，该公司开展了TIDES研究，这是其规模最大的全球试验之一，涉及8个登革热流行国家的20,000名儿童。

In addition to its work on dengue, Takeda has a strong history of producing childhood vaccines, including MMR (measles, mumps, rubella), and has agreements with the Japanese government for pandemic flu preparedness. The company has also contributed to global COVID-19 vaccination efforts by distributing Moderna's vaccine and manufacturing Novavax's vaccine..

除了在登革热方面的工作，武田制药在生产儿童疫苗方面也有很强的历史，包括麻疹、腮腺炎、风疹三联疫苗（MMR），并且与日本政府签订了针对流感大流行的预防协议。该公司还通过分发Moderna的疫苗和生产Novavax的疫苗，为全球COVID-19疫苗接种工作做出了贡献。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)